Discover and read the best of Twitter Threads about #JCO
Most recents (3)
Delighted to share our latest paper in #JCO, in which we suggest an MRD growth model of CLL, including new data from the CLL14 study (Ven-Obi vs Clb-Obi). #leusm #GCLLSG @ASCO_pubs
bit.ly/2ZyAVEZ
Some results in a quick 🧵 1/n
bit.ly/2ZyAVEZ
Some results in a quick 🧵 1/n
1.) We used NGS-based MRD quantification of >2,000 PB samples to devise a non-linear mixed effects model for outlining MRD growth after tx. There was wide heterogeneity in MRD growth trajectories that was dependent on various clinical, serological and genetic characteristics. 
2.) Notably, one of the most important determinant of MRD growth was actually the choice of therapy: Patients who received Ven-Obi had a signif longer MRD doubling time and time to MRD conversion than pts who received chemo with Clb-Obi.
Excited to share the results of @SWOG 1500, which we are presenting at @ASCO #GU21 & reporting in @TheLancet today. 1st, THANK YOU to patients & families. 2nd, hats off to a tremendous group of investigators. This was a team effort! Wanted to share how it all began: (1/13)
A telling snapshot from my "S1500 folder" on my computer. With mentorship from @PrimoLaraMD I submitted the concept 1st in 2012. Had advice from my mentor @DrChoueiri at the time as I conceived of the study design - interestingly, the proposal was XL184 (cabo) v sunitinib! (2/13)
My dear friend @Jeremy_O_Jones helped me w some preclin work & with emerging evidence from the P1 trial that @DrChoueiri #DrMcDermott #DrJanDutcher & I (along with others), we proposed the following formal design to the group in 2013: (3/13)
#OncoAlert Online now @ASCO_pubs - results from CheckMate 153 (continuous vs 1y fixed duration nivolumab for #NSCLC). This was a phase IIIB/IV study of salvage nivo monotherapy. Those with control at 1y were randomized to continue or stop. #LCSM @IASLC
ascopubs.org/doi/full/10.12…
ascopubs.org/doi/full/10.12…
252 patients were randomized and with a minimum f/u of 13.5m, mPFS strongly favored continuous over 1 year (mPFS 24.7 vs 9.4m, HR 0.56). The 1y PFS rate at 12m post-randomization was 65% if nivo continued (44% if stopped). We saw early PFS data at #ESMO17 presented by @dave6408.
New to the #JCO @ASCO_pubs article are survival results. OS strongly favored continuous nivolumab over 1 year fixed dose (HR 0.62). While 1y OS rates were comparable, 2y OS rates were better with continues vs 1y fixed (70% vs 57%). #LCSM
